These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20409618)

  • 41. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening.
    Lin LG; Xie H; Li HL; Tong LJ; Tang CP; Ke CQ; Liu QF; Lin LP; Geng MY; Jiang H; Zhao WM; Ding J; Ye Y
    J Med Chem; 2008 Aug; 51(15):4419-29. PubMed ID: 18610999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.
    Wipf P; Minion DJ; Halter RJ; Berggren MI; Ho CB; Chiang GG; Kirkpatrick L; Abraham R; Powis G
    Org Biomol Chem; 2004 Jul; 2(13):1911-20. PubMed ID: 15227545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
    Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
    J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
    Santarpia L; Ye L; Gagel RF
    J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
    Yu H; Jung Y; Kim H; Lee J; Oh CH; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3805-8. PubMed ID: 20466542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
    Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
    PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery and optimization of selective RET inhibitors via scaffold hopping.
    Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
    Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
    Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of
    Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
    ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships.
    Gavrin LK; Green N; Hu Y; Janz K; Kaila N; Li HQ; Tam SY; Thomason JR; Gopalsamy A; Ciszewski G; Cuozzo JW; Hall JP; Hsu S; Telliez JB; Lin LL
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5288-92. PubMed ID: 16165349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach.
    Saha D; Ryan KR; Lakkaniga NR; Smith EL; Frett B
    ChemMedChem; 2021 May; 16(10):1605-1608. PubMed ID: 33559353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.
    Sartini S; Coviello V; Bruno A; La Pietra V; Marinelli L; Simorini F; Taliani S; Salerno S; Marini AM; Fioravanti A; Orlandi P; Antonelli A; Da Settimo F; Novellino E; Bocci G; La Motta C
    J Med Chem; 2014 Feb; 57(4):1225-35. PubMed ID: 24447248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
    Newton R; Bowler KA; Burns EM; Chapman PJ; Fairweather EE; Fritzl SJR; Goldberg KM; Hamilton NM; Holt SV; Hopkins GV; Jones SD; Jordan AM; Lyons AJ; Nikki March H; McDonald NQ; Maguire LA; Mould DP; Purkiss AG; Small HF; Stowell AIJ; Thomson GJ; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Eur J Med Chem; 2016 Apr; 112():20-32. PubMed ID: 26874741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.
    Jordan AM; Begum H; Fairweather E; Fritzl S; Goldberg K; Hopkins GV; Hamilton NM; Lyons AJ; March HN; Newton R; Small HF; Vishwanath S; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2724-9. PubMed ID: 27086121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current review of small molecule Ret kinase inhibitors.
    Zuercher WJ; Turunen BJ; Lackey KE
    Mini Rev Med Chem; 2010 Feb; 10(2):138-46. PubMed ID: 20105131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
    Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
    J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.